NUVB Nuvation Bio Inc: Earnings per share for the last 12 months

Nuvation Pharma (NUVB) - corporate logo

The integration of new oncology assets has not yet generated strong commercial momentum for Nuvation Bio Inc. (NUVB). The YoY percentage growth of earnings per share over 12 months demonstrates trend inertia, with the 39.50 metric serving as the target level. Outlooks are based on milestone payments for bringing solid tumor therapies to market, provided that external contract manufacturing organizations for small molecules operate reliably.

Nuvation Pharma (NUVB) Earnings per share for the last twelve months: for the period 02/11/2024 - 11/17/2026

NUVB (Nuvation Bio Inc): analytical breakdowns and indicator data

- price and consensus price forecast:
Fundamental company valuation:NUVB Nuvation Pharma
Flagship merchandise of Nuvation Bio

For the biopharmaceutical sector, where Nuvation Bio Inc. (NUVB) invests in taletrectinib and the acquisition of AnHeart Therapeutics, the year-over-year EPS trend (trailing 12 months) serves as an indicator of how effectively existing cash reserves are being capitalized. This metric measures the percentage change in net income per share over a rolling year, allowing investors to assess business scaling rates and the asset's fundamental stability.

Direct competitors

Net earnings per one share for the last twelve months Incyte Corp|HCM: Net earnings per share (EPS TTM)|Earnings per share for the last 12 months DAWN|MNPR (monopartx.com) - Net earnings per share (EPS TTM)|Net earnings per share for the last 12 months inhibrx.com (INBX)|Earnings per share for the last twelve months I-Mab (IMAB)|FENC - Net earnings per one share for the last twelve months|Earnings per share for the last twelve months Heron Therapeutics Inc HRTX|Nuvectis Pharma, Inc - Earnings per share for the last twelve months|CHRS - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months Corbus Pharmaceuticals|CRDF: Net earnings per share (EPS TTM)|Net earnings per share for the trailing year BeyondSpring Pharma BYSI|Net earnings per share for the last 12 months BCAB|Net earnings per one share for the last twelve months Lixte Biotechnology LIXT|Net earnings per share for the last 12 months CTXR (Citius Pharmaceuticals Inc.)|CLRB (Cellectar Biosciences, Inc.) - Earnings per share for the trailing year|BioLineRx Ltd. - Net earnings per share for the last 12 months|Earnings per share for the last four quarters CANF (Can-Fite BioPharma Ltd.)|Aprea Therapeutics, Inc. - Net earnings per share (EPS TTM)|Earnings per share for the trailing year KZIA (kaziatherapeutics.com)|SLXN: Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months NuCana Corp (NCNA)|Earnings per share for the last twelve months Chimerix|CYCC: Earnings per share for the trailing year|Net earnings per share (EPS TTM) GTHX|Net earnings per share (EPS TTM) Kronos Bio Corporation (KRON)|Earnings per share for the last twelve months Kintara KTRA|ONCT (Oncternal Therapeutics, Inc.) - Earnings per one share for the last 12 months|PRTG: Net earnings per share for the last 12 months